2026 NPPES data Hematology & Oncology Physician NPI 1588906457 M.D., PH.D
Verify on CMS →

GARY LU, M.D., PH.D

Hematology & Oncology Physician in DENTON, Texas. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
973
Medicare Part D claims · 161 beneficiaries · Hematology & Oncology Physician avg: 847
Generic prescribing
88%
generic claims · 12% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
89.4449/100
▲ 6 pts above national avg 83.1 · [object Object]
Industry payments
$1.0K
20 payments · CMS Open Payments (Sunshine Act)

What the federal data shows

GARY LU, M.D., PH.D reported a CMS MIPS final score of 89.4449/100 — above the 83.1 national average — and filed 973 Medicare Part D claims in 2023.

89.4449/100
MIPS score · +6 vs avg
973
Part D claims, 2023
88%
generic prescribing
Likely
board-certified (heuristic)

Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.

GARY LU, M.D., PH.D's MIPS score vs every scored U.S. clinician

CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure

89 Top 42% higher than 58% of 477,587 scored providers

0–10: 8,684 scored providers (2%). Below this entry. 10–20: 3,008 scored providers (1%). Below this entry. 20–30: 3,069 scored providers (1%). Below this entry. 30–40: 2,746 scored providers (1%). Below this entry. 40–50: 2,928 scored providers (1%). Below this entry. 50–60: 5,882 scored providers (1%). Below this entry. 60–70: 13,906 scored providers (3%). Below this entry. 70–80: 118,074 scored providers (25%). Below this entry. 80–90: 129,887 scored providers (27%). This entry sits in this band. 90–100: 189,403 scored providers (40%). Above this entry. This provider 0 100 every MIPS-scored clinician, bucketed by value

Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Merit-based Incentive Payment System (MIPS) · 2023

Board certification likely (heuristic — not verified)

GARY LU, M.D., PH.D practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 1 hospital affiliation — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).

What does the federal data show about GARY LU, M.D., PH.D?

High performer (top quartile)

NPI registry status

Active

Issued 03/19/2013

NPI 1588906457

Primary specialty

Hematology & Oncology Physician

Mid-sized

11,215 US NPIs in this specialty

Medicare Part D claims

973 15% vs specialty avg

2023 prescription claims

Specialty avg: 847

MIPS final score

89.4449/100 6.34490000000001% pts

Exceptional band

vs 83.1 national avg

Specialty distribution in Texas

How Hematology & Oncology Physician compares to other specialties among Texas providers

Texas providers

Hematology & Oncology Physician share within Texas

1. Hematology & Oncology Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Hematology & Oncology Physician share within Texas

Medicare quality performance — MIPS

GARY LU, M.D., PH.D's 2023 MIPS final score plotted against the Hematology & Oncology Physician national average

High performer (top quartile)
MIPS Final Score
89.4449/100
vs 83.1 national avg · 2023 performance year

MIPS final score (Hematology & Oncology Physician) — 89.4449/100 vs national avg 83.1

0%100%National avg83%89.4%
MIPS final score (Hematology & Oncology Physician) — 89.4449/100 vs national avg 83.1

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

GARY LU, M.D., PH.D appears in the CMS NPPES registry as a Hematology & Oncology Physician provider holding M.D., PH.D credentials at 2600 SCRIPTURE ST, DENTON, TX, 76201, with a listed phone of (940) 382-1022. NPI 1588906457 was issued on 03/19/2013. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what LU most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 973 prescription claims written by this provider, covering 161 Medicare beneficiaries and totaling roughly $732K in drug spend, split 12% brand-name and 88% generic by claim count, with an opioid prescribing rate of 13.2%. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 89.4449/100 for the 2023 performance year (Quality 75.8575), compared with the national average of 83.1.

Hematology & Oncology Physician is a mid-sized specialty nationwide, with 11,215 enrolled providers across 54 states and an average of 847 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

2600 SCRIPTURE ST
DENTON, TX 76201

Provider Details

NPI 1588906457
Specialty Hematology & Oncology Physician
Credentials M.D., PH.D
Gender Male
NPI Issued 03/19/2013

CMS Quality Score (MIPS)

Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.

89.4449
Final Score
Avg: 83.1
75.8575
Quality
100
Promoting Interoperability

Reporting: Alternative Payment Model

Hospital and facility affiliations

Facilities where GARY LU, M.D., PH.D bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.

TEXAS ONCOLOGY PA
DENTON, TX

Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).

Industry payments received (2024) — CMS Open Payments transparency data

The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for GARY LU, M.D., PH.D. Source: openpaymentsdata.cms.gov.

Total received

$1.0K

Largest payer

Novartis Pharmaceuticals Corporation

Most common payment type

Food and Beverage

Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.

License & disciplinary context — Texas TMB 2023 annual report

Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~77K Texas medical licensees in 2023 — they are NOT specific to GARY LU, M.D., PH.D. To verify GARY LU, M.D., PH.D's current license status, search the TMB public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

344
Total board actions, Texas 2023
Across 334 cases
4.47
Actions per 1,000 licensees
Texas statewide rate
probation
Most common action type
94 cases

TMB publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Texas disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Brand vs generic prescribing mix · Typical

GARY LU, M.D., PH.D — brand share 12.0%
Specialty average (est.)

12% brand-name claims vs 88% generic, on 973 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

973
Total Claims
$732K
Total Drug Cost
161
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
1,248
Total Day Supply
28,940
Brand vs Generic
12% brand / 88% generic
Brand Drug Cost
$606K
Generic Drug Cost
$126K
Opioid Claims
128 (13.2% rate)
Antibiotic Claims
40

Patient Demographics

Average Patient Age
73.9 years
Avg HCC Risk Score
2.06
Gender Split
66% female / 34% male

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

What GARY LU, M.D., PH.D prescribes most

Top Medicare Part D drugs by claim count, 2023

claims
Source CMS Medicare Part D Prescriber Public Use File As of 2023
Drug Claims
Anastrozole
88
Dexamethasone
80
Prednisone
66
Hydrocodone-Acetaminophen
Hydrocodone/Acetaminophen
53
Letrozole
46
Acyclovir
41
Potassium Chloride
33
Gabapentin
30
Ondansetron Odt
Ondansetron
28
Morphine Sulfate Er
Morphine Sulfate
24

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Hematology & Oncology Physician Overview

How GARY LU, M.D., PH.D fits within the Hematology & Oncology Physician landscape nationally.

11,215
Hematology & Oncology Physician Providers in US
54
States with Hematology & Oncology Physician
847
Avg Claims per Provider

GARY LU, M.D., PH.D's 973 claims are above the specialty average of 847.

Nearby Hematology & Oncology Physician Providers in Texas

Other clinicians with the same primary specialty enrolled in Texas, drawn from the same CMS NPPES roster as LU.

Compare Hematology & Oncology Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is GARY LU, M.D., PH.D's specialty?
GARY LU, M.D., PH.D specializes in Hematology & Oncology Physician and practices in DENTON, Texas. Credentials: M.D., PH.D.
How much does GARY LU, M.D., PH.D prescribe under Medicare Part D?
In 2023, GARY LU, M.D., PH.D wrote 973 Medicare Part D claims totaling $732K in drug costs for 161 beneficiaries.
What is GARY LU, M.D., PH.D's Medicare quality score?
GARY LU, M.D., PH.D has a CMS MIPS Final Score of 89.4449/100 (Quality: 75.8575). The national average MIPS Final Score is 83.1. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is GARY LU, M.D., PH.D located?
GARY LU, M.D., PH.D is located at 2600 SCRIPTURE ST, DENTON, TX, 76201. Phone: (940) 382-1022.
What is GARY LU, M.D., PH.D's NPI number?
GARY LU, M.D., PH.D's National Provider Identifier (NPI) is 1588906457, issued on 03/19/2013.
Does GARY LU, M.D., PH.D prescribe more brand-name or generic drugs?
GARY LU, M.D., PH.D's prescribing is 12% brand-name and 88% generic drugs by claim count, with $606K in brand drug costs.
Does GARY LU, M.D., PH.D prescribe opioids?
Yes, GARY LU, M.D., PH.D had 128 opioid claims in 2023 with an opioid prescribing rate of 13.2%.
How many Hematology & Oncology Physician providers are there in the US?
There are 11,215 Hematology & Oncology Physician providers across 54 states in the US. The average Hematology & Oncology Physician provider writes 847 Medicare Part D claims per year.
What drugs does GARY LU, M.D., PH.D prescribe most often?
Based on 2023 Medicare Part D data, GARY LU, M.D., PH.D's most frequently prescribed drugs include Anastrozole, Dexamethasone, Prednisone. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does GARY LU, M.D., PH.D accept Medicare?
GARY LU, M.D., PH.D appears in CMS Medicare data with 973 Part D claims and 161 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify GARY LU, M.D., PH.D's credentials?
GARY LU, M.D., PH.D's NPI is 1588906457 with credentials M.D., PH.D. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Quality Performance
CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology